Yahoo Finance Should USANA Health Sciences (NYSE:USNA) Be Disappointed With Their 53% Profit?
Passive investing in index funds can generate returns that roughly match the overall market. But you can do a lot better than that by buying good quality businesses for attractive prices. For example, the USANA Health Sciences, Inc. (NYSE:USNA) share price is 53% higher than it was five years ago, which is more than the market average. Zooming in, the stock is actually down 30% in the last year.
Check out our latest analysis for USANA Health Sciences
To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
During five years of share price growth, USANA Health Sciences achieved compound earnings per share (EPS) growth of 9.6% per year. So the EPS growth rate is rather close to the annualized share price gain of 8.8% per year. That suggests that the market sentiment around the company hasn't changed much over that time. Indeed, it would appear the share price is reacting to the EPS.
The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).
We know that USANA Health Sciences has improved its bottom line lately, but is it going to grow revenue? Check if analysts think USANA Health Sciences will grow revenue in the future.
A Different Perspective
Investors in USANA Health Sciences had a tough year, with a total loss of 30%, against a market gain of about 37%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 8.8%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. If you would like to research USANA Health Sciences in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
